Trial · NCT05044195
Results by group188
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 188
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | A/H1N1 | 731.90 | 95% Confidence Interval 689.39 to 777.04 | Titer |
| Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | A/H1N1 | 586.85 | 95% Confidence Interval 552.83 to 622.96 | Titer |
| Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | A/H3N2 | 347.89 | 95% Confidence Interval 324.78 to 372.64 | Titer |
| Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | A/H3N2 | 313.16 | 95% Confidence Interval 292.42 to 335.36 | Titer |
| Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | B/Yamagata | 154.40 | 95% Confidence Interval 146.80 to 162.40 | Titer |
| Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | B/Yamagata | 145.74 | 95% Confidence Interval 138.57 to 153.27 | Titer |
| Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | B/Victoria | 144.41 | 95% Confidence Interval 136.97 to 152.26 | Titer |
| Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | B/Victoria | 143.32 | 95% Confidence Interval 135.97 to 151.07 | Titer |
| Immunogenicity Endpoint: Seroconversion Rate (SCR) and SCR Difference for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | A/H1N1 | 81.2 | 95% Confidence Interval 78.57 to 83.58 | percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rate (SCR) and SCR Difference for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | A/H1N1 | 76.8 | 95% Confidence Interval 74.04 to 79.42 | percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rate (SCR) and SCR Difference for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | A/H3N2 | 63.6 | 95% Confidence Interval 60.46 to 66.63 | percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rate (SCR) and SCR Difference for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | A/H3N2 | 61.8 | 95% Confidence Interval 58.61 to 64.82 | percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rate (SCR) and SCR Difference for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | B/Yamagata | 43.4 | 95% Confidence Interval 40.27 to 46.60 | percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rate (SCR) and SCR Difference for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | B/Yamagata | 41.0 | 95% Confidence Interval 37.92 to 44.19 | percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rate (SCR) and SCR Difference for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | B/Victoria | 44.5 | 95% Confidence Interval 41.39 to 47.74 | percentage of participants |
| Immunogenicity Endpoint: Seroconversion Rate (SCR) and SCR Difference for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | B/Victoria | 40.6 | 95% Confidence Interval 37.52 to 43.76 | percentage of participants |
| Immunogenicity Endpoint: GMT and GMT Ratio of HI Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | A/H1N1 | 729.17 | 95% Confidence Interval 687.51 to 773.36 | Titer |
| Immunogenicity Endpoint: GMT and GMT Ratio of HI Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | A/H1N1 | 589.07 | 95% Confidence Interval 555.25 to 624.94 | Titer |
| Immunogenicity Endpoint: GMT and GMT Ratio of HI Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | aQIV | A/H3N2 | 347.09 | 95% Confidence Interval 324.44 to 371.33 | Titer |
| Immunogenicity Endpoint: GMT and GMT Ratio of HI Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and B/Victoria Vaccine Strains | Comparator QIV | A/H3N2 | 315.69 | 95% Confidence Interval 295.04 to 337.79 | Titer |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05044195/results